A 2026 methylome-wide association study by Shen et al. found 48 CpG methylation sites tied to the quadratic CYP2C19 metabolizer-status term in 18,396 Generation Scotland participants, with 19 sites showing non-linear patterns and targeted replication in 1,238 older adults.1 That supports CYP2C19 as real biology beneath SSRI pharmacogenomics, but it does not prove universal antidepressant …
A 2026 retrospective case series of 22 adults with treatment-resistant depression and comorbid PTSD found that trauma re-experiencing during intranasal esketamine disappeared over later sessions in 72.7% of patients, while 27.3% stopped esketamine because the flashbacks persisted.1 Research Highlights Flashbacks usually faded, but not always: In 16 of 22 patients (72.7%), esketamine-related trauma re-experiencing disappeared …
A 2026 male-mouse study found that 30 mg/kg dexamethasone for 5 days increased light-phase wakefulness (t13 = 4.122, p = 0.0012), decreased NREM sleep (t13 = 4.412, p = 0.0007), and amplified orexin-neuron activity during NREM-to-wake transitions (F1,9 = 6.941, p = 0.0272). The result points to orexin-linked hyperarousal as a testable explanation for steroid-induced …
A 2026 nuMoM2b Heart Health Study analysis tested whether urine-confirmed cannabis exposure 2–7 years after a first pregnancy predicted incident stage II hypertension; it did not: adjusted odds ratio (AOR) 1.05, 95% CI 0.63–1.76, with 216 of 4,079 participants developing hypertension.1 Research Highlights The headline result was null: cannabis exposure at the 2–7 year postpartum …
Most antidepressant pharmacovigilance data come from high-income countries, leaving prescribing patterns and adverse-effect profiles in low- and middle-income countries underdocumented. A 2026 cross-sectional study by Riaz and colleagues describes antidepressant use in Pakistan, with patient-reported adverse effects mapped against prescription patterns.1 Research Highlights Antidepressant use in low- and middle-income countries (LMICs) has grown substantially but …
The risperidone-stroke link in dementia is one of the longest-running safety signals in geriatric psychiatry, anchoring the FDA’s 2005 black-box warning on atypical antipsychotic mortality. Popular framing reduces it to “antipsychotics cause stroke in dementia” — a true sentence that flattens a multi-axis decision. Choma’s 2025 analysis of UK primary care records is the largest …
Alcohol’s effects on the brain, especially among the elderly, have long been a subject of scientific inquiry. A recent study from Gothenburg, Sweden, provides new insights into how varying levels of alcohol consumption impact brain structure in individuals aged 70 and over. This research sheds light on the relationship between alcohol intake and the aging …